// App-Quantinova.ai

: Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Researchers

Presenter

  • Sylvain Garciaz

Principal Investigators

  • Andrew Guirguis

  • Fiona C. Brown

  • Yih-Chih Chan

  • Mathilde Poplineau

  • Kevin Tran

  • Kah-Lok Chan

  • Laura MacPherson

  • Brian Liddicoat

  • Enid Y. N. Lam

  • Tatiana Cañeque

  • Marian L. Burr

  • Veronique Litalien

  • Giovanna Pomilio

  • Estelle Duprez

  • David C.S. Huang

  • Sarah-Jane Dawson

  • Georg Ramm

  • Andrew G. Cox

  • Kristin K. Brown

  • Andrew H. Wei

  • Kate McArthur

  • Raphael Rodriguez

  • Mark A. Dawson

Medical Centers

  • Monash University, Australian Centre for Blood Diseases, Melbourne, Australia

  • Institut Paoli-Calmettes, CRCM, Marseille, France

  • Monash University, Clayton, Australia

  • Peter MacCallum Cancer Centre, MELBOURNE, Australia

  • Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia

  • CRCM, Marseille, France

  • Institut Curie, PARIS, France

  • Centre de Recherche en Cancerologie de Marseille, Marseille, France

  • The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

  • Institut Paoli Calmettes, Institut Paoli-Calmettes, Marseille, France

  • The Alfred Hospital and Monash University, Melbourne, Australia

Locations

  • Australia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • BCL2 associated X, apoptosis regulator

  • B-cell lymphoma 2

  • Poly(ADP-Ribose) Polymerase 1

Drug/Treatment

  • Ferrostatin-1

  • Nicotinamide

  • Venetoclax

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved